Trial Profile
Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Jan 2024
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Bevacizumab; Pazopanib
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms START
- 11 Jan 2024 Planned End Date changed from 31 Jan 2024 to 31 Jan 2025.
- 11 Jan 2024 Planned primary completion date changed from 31 Jan 2024 to 31 Jan 2025.
- 02 Feb 2023 Planned End Date changed from 31 Jan 2023 to 31 Jan 2024.